CSF2 and lung carcinoma: After administration, controlled degradation of ISHs could ensure persistent release of antigen-loaded nano-sized polyplexes and granulocyte-macrophage colony-stimulating factor (GM-CSF), thereby effectively suppressing human lung carcinoma in vivo [64].